We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs.
- Authors
Campese, Vito
- Abstract
HMG-CoA reductase inhibitors (statins) have been shown to reduce cardiovascular morbidity in patients with normal and abnormal kidney function but not in patients with end-stage kidney disease. Evidence supports a role for statins in delaying the progression of kidney disease in a variety of experimental models in animals. However, the evidence that statins may retard CKD progression in humans is scant. In this review, we critically consider the available data supporting a role for statins in CKD progression in humans and the possibility that there might be differences among statins in regards to effects on the kidneys. Finally, we review the evidence that statins may increase the risk of acute kidney injury.
- Subjects
STATINS (Cardiovascular agents); DYSLIPIDEMIA; ANTILIPEMIC agents; CARDIOVASCULAR diseases; CHRONIC kidney failure; KIDNEY injuries; ANIMAL models in research
- Publication
Clinical & Experimental Nephrology, 2014, Vol 18, Issue 2, p291
- ISSN
1342-1751
- Publication type
Academic Journal
- DOI
10.1007/s10157-014-0934-9